NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION

NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION

Cambridge, UK. (7 November 2008) Quotient Bioresearch, a leading provider of early phase drug development and sports testing services, today announces that it is investing in its development with the purchase of three Thermo Scientific LTQ Orbitrap™ XL mass spectrometers.This significant investment demonstrates Quotient Bioresearch’s commitment to offering the highest quality service to its customers.

QUOTIENT RECEIVES STRATEGIC INVESTMENT OF £35 MILLION From TA ASSOCIATES

Proceeds to be used to fund aquisition-led and organic growth strategy.

QUOTIENT CONSOLIDATES DRUG DEVELOPMENT BUSINESSES

Businesses now fully integrated and Quotient seeking further acquisitions

QUOTIENT BIORESEARCH ACQUIRES BIODYNAMICS RESEARCH LTD

Further expansion for Quotient BioResearch in drug development services through the acquisition of BioDynamics Research, builds capacity and service offerings

QUOTIENT BIORESEARCH LAUNCHED WITH ACQUISITIONS OF HFL LIMITED

Quotient BioResearch Ltd today announced its launch with the acquisition of HFL Ltd, a leading UK provider of sports forensic testing and pharmaceutical research and development services, from the Horseracing Betting Levy Board.